Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.
Bad Marienberg (www.aktiencheck.de) - Spyre Therapeutics: Deutsche Bank startet mit Rating "buy" und Kursziel 43 USD - Warum die Erstanalyse enormes Aufwärtspotenzial siehtEin...
The human microbiome market is projected to expand at a CAGR of 20.42%, growing from $941.215 million in 2025 to $2.38 billion by 2030. This growth is driven by rising lifestyle...
Wall Streets main indexes were on track for a lower open on Tuesday as the Israel-Iran conflict entered its fifth day, denting global investor confidence ahead of the Federal...
The mean of analysts price targets for Seres Therapeutics (MCRB) points to a 713.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective,...
